Eravacycline, a newly approved fluorocycline

Complicated intra-abdominal infections (cIAIs) are commonly associated with multimicroorganisms and treatment choices are becoming narrower due to developing resistance, especially in the gram-negative Enterobacteriaceae species. Eravacycline is a newly developed, fully synthetic tetracycline deriva...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of clinical microbiology & infectious diseases 2019-10, Vol.38 (10), p.1787-1794
Main Authors:	Lee, Young Ran, Burton, Caitlin Elizabeth
Format:	Article
Language:	eng
Subjects:	Administration, Intravenous Administration, Oral Anaerobic microorganisms Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Bacteria, Anaerobic - drug effects Biomedical and Life Sciences Biomedicine Clinical trials Clinical Trials as Topic Coinfection - drug therapy Drug Approval Drug resistance E coli Enterobacteriaceae Ertapenem Formulations Gram-Negative Bacteria - drug effects Gram-Negative Bacterial Infections - drug therapy Gram-Positive Bacteria - drug effects Gram-Positive Bacterial Infections - drug therapy Humans Infections Internal Medicine Intraabdominal Infections - drug therapy Levofloxacin Medical Microbiology Medical research Meropenem Methicillin Microbial Sensitivity Tests Microorganisms Minimum inhibitory concentration Review Tetracyclines - pharmacology Tetracyclines - therapeutic use Treatment Outcome Urinary tract Vancomycin β Lactamase
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Complicated intra-abdominal infections (cIAIs) are commonly associated with multimicroorganisms and treatment choices are becoming narrower due to developing resistance, especially in the gram-negative Enterobacteriaceae species. Eravacycline is a newly developed, fully synthetic tetracycline derivative that has shown potent broad-spectrum activity against a wide variety of microorganisms, including those such as extended spectrum β-lactamase producing Enterobacteriaceae and Acinetobacter . Eravacycline has shown activity against many gram-positive organisms such as methicillin-resistant S. aureus and vancomycin resistant Enterococcus faecalis and Enterococcus faecium (VRE), gram-negative organisms such as Escherichia coli , and anaerobic species of microorganisms such as Bacteroides . This fluorocycline has been compared to ertapenem and meropenem for the treatment of complicated intra-abdominal infections and levofloxacin for the treatment of complicated urinary tract infections. Eravacycline was shown to be noninferior to ertapenem but did not meet noninferiority criteria in comparison to levofloxacin. Oral and IV formulations on eravacycline were tested in clinical trials, but at this time, only the IV formulation is FDA approved. Eravacycline has been noted to have a half-life of 20 h with protein binding around 80%; AUC over minimum inhibitory concentration (MIC) has also been shown to be eravacycline’s best predictor of efficacy. Of note, eravacycline does not require any renal dose adjustments, as the majority of its clearance is by nonrenal pathways.
ISSN:	0934-9723 1435-4373